
Across the trials, abrocitinib demonstrated a consistent safety profile and profound improvements in skin clearance, extent of disease, and severity.

Across the trials, abrocitinib demonstrated a consistent safety profile and profound improvements in skin clearance, extent of disease, and severity.

It is important for pharmacists to know the latest updates on the right treatment options for atopic dermatitis.

Dupilumab has been a breakthrough treatment for patients with atopic dermatitis, but future studies are needed to continue learning about its strength.

Eli Lilly says the drug in combination with TCS also achieved all key secondary endpoints versus the placebo for individuals with AD.